Clinical Trial

Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
Trial Details
NCT Number NCT07403552
Lead Sponsor Ensho Therapeutics, Inc.
Conditions Healthy
Enrollment 24 participants
Start Date 2026-01-31
Primary Completion 2026-03 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-11